Gender, male | 21/28 (75%) | EF (%) | 50 [45–55] |
Age (years) | 69 [61–77] | MAP (mmHg) | 83 [73.3–86.3] |
BMI (kg/m2) | 27.5 [24.5–32.6] | HR (bpm) | 80 [69.3–85.5] |
Time from onset of symptoms to ICU admission (days) | 9 [7–12.25] | Vasoactive drugs | 10/28 (35.7%) |
NIV on admission | 16/28 [57.2%] | Age-adjusted Charlson Comorbidity Index | 4 [2.75–4.25] |
ETT on admission | 12/28 [42.8%] | SOFA score | 3 [2–5] |
PaO2/FiO2 ratio | 146.5 [111.5–152.5] | Pct ug/L (0–0.5) | 0.34 [0.09–1.06] |
PEEP (cmH2O) | 12 [10–12] | proBNP ng/L (0–100) | 55 [31–124] |
Admission | Discharge | ||
Global LUS score | 27.5 [21–32.25] | Global LUS score | 31 [24.75–33] |
LUS score survivors | 28 [20.5–32] | LUS score survivors | 31 [17.5–32.75] |
LUS score non-survivors | 25 [21–32.5] | LUS score non-survivors | 30.5 [27–32.75] |
LUS score right lung | 13 [10.75–16] | LUS score right lung | 14.5 [11.75–16.25] |
LUS score left lung | 15 [10.75–17] | LUS score left lung | 16 [13–18] |